Loading…
Loading…
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's
The Company's Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM's Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that the Company has received an additional order for its electronic readers designed to analyze both of the Company's proprietary diagnostics assays from its commercialization partner Verséa Ophthalmics.
Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays
SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the receipt of notification by the United States Patent & Trademark Office of several patent allowances. AXIM has been developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including, for example, SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9. This inn.
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced the development of the second generation version of its Rapid Neutralizing Antibody Test for COVID-19.
Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board
No recent filings indexed.